Safer and more efficient methods for directing therapeutic genes to specific sequences could increase the repertoire of treatable conditions. Many current approaches act passively， first initiating a double-stranded break， then relying on host repair to uptake donor DNA. Alternatively， we delivered an actively integrating transposase to the target sequence to initiate gene insertion. We fused the hyperactive transposase to the highly specific， catalytically dead SpCas9-HF1 (dCas9) and designed guide RNAs (gRNAs) to the CCR5 safe harbor sequence. We introduced mutations to the native DNA-binding domain of to reduce non-specific binding of the transposase and cause the fusion protein to favor binding by... More
Safer and more efficient methods for directing therapeutic genes to specific sequences could increase the repertoire of treatable conditions. Many current approaches act passively， first initiating a double-stranded break， then relying on host repair to uptake donor DNA. Alternatively， we delivered an actively integrating transposase to the target sequence to initiate gene insertion. We fused the hyperactive transposase to the highly specific， catalytically dead SpCas9-HF1 (dCas9) and designed guide RNAs (gRNAs) to the CCR5 safe harbor sequence. We introduced mutations to the native DNA-binding domain of to reduce non-specific binding of the transposase and cause the fusion protein to favor binding by dCas9. This strategy enabled us， for the first time， to direct transposition to the genome using RNA. We showed that increasing the number of gRNAs improved targeting efficiency. Interestingly， over half of the recovered insertions were found at a single TTAA hotspot. We also found that the fusion increased the error rate at the genome-transposon junction. We isolated clonal cell lines containing a single insertion at CCR5 and demonstrated long-term expression from this locus. These vectors expand the utility of the system for applications in targeted gene addition for biomedical research and gene therapy.
